Fabtech Technologies IPO
Fabtech Technologies IPO Price Range is ₹181 - ₹191, with a minimum investment of ₹14,325 for 75 shares per lot.
Subscription Rate
2.03x
as on 01 Oct 2025, 07:31PM IST
Minimum Investment
₹14,325
/ 75 shares
IPO Status
Price Band
₹181 - ₹191
Bidding Dates
Sep 29, 2025 - Oct 1, 2025
Issue Size
₹230.35 Cr
Lot Size
75 shares
Min Investment
₹14,325
Listing Exchange
BSE
IPO Doc
Fabtech Technologies IPO Application Timeline
IPO Subscription Status
as on 01 Oct 2025, 07:31PM IST
IPO subscribed over
🚀 2.03x
This IPO has been subscribed by 2.084x in the retail category and 2.018x in the QIB category.
Subscription Rate
| Total Subscription | 2.03x |
| Retail Individual Investors | 2.084x |
| Qualified Institutional Buyers | 2.018x |
| Non Institutional Investors | 1.967x |
Objectives of IPO
- Fabtech Technologies Limited is raising ₹230.35 crore via its IPO, which is entirely a Fresh Issue of equity shares. Since there is no Offer for Sale (OFS), all the funds raised will go directly to the company.
- Out of the money raised, Fabtech plans to use about ₹127 crore to meet its working capital requirements. This will help the company manage day-to-day operations in its working-capital intensive business.
- Around ₹30 crore will be set aside for acquisitions and partnerships, allowing Fabtech to expand its manufacturing capabilities, diversify its customer base, and grow in markets such as India, the UAE, Saudi Arabia, and Egypt.
- The balance funds will be used for general corporate purposes, including marketing, salaries, administrative expenses, and technology upgrades. As per SEBI guidelines, the amount allocated under this head will not exceed 25% of the Gross Proceeds, and together with acquisitions, it will not exceed 35% of the Gross Proceeds.
Financial Performance of Fabtech Technologies
Fabtech has shown strong growth over the last three years. Revenue has climbed from ₹200 crore in FY23 to ₹336 crore in FY25, a CAGR of nearly 30%. Assets have also expanded rapidly, growing at 41% CAGR, which points to an aggressive scale-up.
Profits have risen steadily too, from ₹22 crore in FY23 to ₹46 crore in FY25, a CAGR of 46%. This shows the business is not just growing bigger, but also generating more earnings for shareholders.
Margins, however, tell a mixed story. EBITDA margin, which was 16.2% in FY23 and 17.2% in FY24, slipped to 14.1% in FY25, showing some pressure on operating efficiency. On the other hand, PAT margin has improved consistently, rising from 10.9% in FY23 to 13.8% in FY25, which indicates better cost control and higher net profitability.
Overall, Fabtech is scaling up quickly with strong profit growth. While operating margins have softened, steady improvement in net margins highlights a healthier bottom line and efficient financial management.
Strengths and Risks
Strengths
Fabtech Technologies Limited reported strong growth, with total revenue rising from ₹199.9 crore in FY23 to ₹335.9 crore in FY25, a CAGR of nearly 30%. Profit after tax more than doubled in the same period to ₹46.5 crore, with PAT margins improving to 13.8%.
Turnkey services contributed 76% of revenue in FY25, underlining Fabtech’s position as a leading end-to-end engineering solutions provider in the pharmaceutical capex space. Its order book has also scaled rapidly, reaching ₹9,044 crore as of July 31, 2025.
The company’s strength lies in its integrated, asset-light business model and proven track record across diverse dosage forms, from tablets and capsules to injectables and inhalers. With a presence in over 62 countries, Fabtech has successfully delivered projects in complex markets such as the GCC, MENA, and ECO regions.
Risks
Fabtech Technologies Limited reported revenue of ₹335.9 crore in FY25 with profits of ₹46.5 crore and a PAT margin of 13.8%. However, the business remains highly working capital intensive, with 195 working capital days as of July 31, 2025. Over 55% of receivables, worth ₹849 crore, were overdue by more than six months, which could strain cash flows and affect project execution.
The company’s order book has scaled to ₹9,044 crore, but is concentrated, with the top five projects contributing over 62% in FY25. Delays or cancellations, contracts worth ₹1,349 crore were already delayed as of July 2025, or cost overruns in its fixed-price contracts could materially impact profitability.
Fabtech derives nearly 74% of its revenue from the pharmaceutical, healthcare, and biotech sectors, and is heavily exposed to overseas markets such as the GCC and MENA regions. Any slowdown in industry capex cycles, regulatory changes, or geopolitical instability in these regions could reduce project demand and revenue visibility.
The company relies on related parties and third-party suppliers for equipment, without long-term supply agreements. This exposes it to risks of higher costs, delays, or conflicts of interest. It also carries contingent liabilities of over ₹3,100 crore from guarantees, which could pressure finances if invoked.
How to Apply for Fabtech Technologies IPO on INDmoney
- Download the INDmoney app and complete your KYC.
- Go to INDstocks → IPO, or just search “IPO”.
- Tap on Fabtech Technologies IPO from the list of live IPOs.
- View key details like price band, lot size, and dates.
- Tap Apply Now and choose your number of lots.
- Use INDpay UPI for instant mandate tracking.
- Your funds will be blocked until the share allotment is finalized.
Fabtech Technologies Shareholding Pattern
| Promotor | 94.61% | |
| Name | Role | Stakeholding |
| Aasif Ahsan Khan | Promoter | 56.98% |
| Hemant Mohan Anavkar | Promoter | 11.76% |
| Aarif Ahsan Khan | Promoter | 14.11% |
| Manisha Hemant Anavkar | Promoter | 11.76% |
| Public | 5.39% | |
| Name | Role | Stakeholding |
| Raj Narendra Mehta | Public | 1.03% |
| Others | 4.36% |
About Fabtech Technologies
Fabtech Technologies provides comprehensive, start-to-finish project execution (known as turnkey solutions). This includes design, engineering, procurement, installation, testing, and commissioning for complex aseptic manufacturing facilities, focusing on three operational areas: bio clean air, clean water, and process. They have a track record executing projects for various dosage forms (liquids, solids, semisolids).
Fabtech operates on a scalable, asset-light model by primarily sourcing equipment from related entities within the Fabtech Group and third-party suppliers, which helps minimize capital investment in manufacturing.They operate across more than 62 countries, targeting key emerging economies (including GCC, MENA, and ECO regions).
For more detail visit the company website, fabtechnologies.com
Frequently Asked Questions of Fabtech Technologies IPO
What is the size of the Fabtech Technologies IPO?
What is the allotment date of the Fabtech Technologies IPO?
What are the open and close dates of the Fabtech Technologies IPO?
What is the lot size of Fabtech Technologies IPO?
When will my Fabtech Technologies IPO order be placed?
Can we invest in Fabtech Technologies IPO?
What would be the listing gains on the Fabtech Technologies IPO?
What is 'pre-apply' for Fabtech Technologies IPO?
Who are the promoters of Fabtech Technologies?
The promoters of Urban Company are Aasif Ahsan Khan, Hemant Mohan Anavkar, Aarif Ahsan Khan, and Manisha Hemant Anavkar. These founders collectively hold 94.61% of the company's fully diluted share capital as of the Red Herring Prospectus date.
How does Fabtech Technology make money?
Fabtech Technology earns revenue mainly by providing turnkey engineering solutions in the pharmaceutical capex space, along with standalone services like equipment supply, installation, and commissioning. In FY24, turnkey projects contributed 87% of revenue, while standalone services made up 13%. By FY25, turnkey’s share dipped to 76%, with standalone services rising to 24%, showing a growing diversification in its business mix.